TY - JOUR AU - Theriault, R. L. AU - Carlson, R. W. AU - Allred, C. AU - Anderson, B. O. AU - Burstein, H. J. AU - Edge, S. B. PY - 2013 DA - 2013// TI - Breast cancer, version 3.2013: featured updates to the NCCN guidelines JO - J Natl Compr Canc Netw VL - 11 ID - Theriault2013 ER - TY - JOUR AU - Cardoso, F. AU - Costa, A. AU - Norton, L. AU - Senkus, E. AU - Aapro, M. AU - Andre, F. PY - 2014 DA - 2014// TI - ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)dagger JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu385 DO - 10.1093/annonc/mdu385 ID - Cardoso2014 ER - TY - JOUR AU - Andre, F. AU - Slimane, K. AU - Bachelot, T. AU - Dunant, A. AU - Namer, M. AU - Barrelier, A. PY - 2004 DA - 2004// TI - Breast cancer with synchronous metastases: trends in survival during a 14-year period JO - J Clin Oncol. VL - 22 UR - https://doi.org/10.1200/JCO.2004.08.095 DO - 10.1200/JCO.2004.08.095 ID - Andre2004 ER - TY - JOUR AU - Buzdar, A. U. PY - 2004 DA - 2004// TI - Phase III, study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group JO - J Clin Oncol. VL - 22 UR - https://doi.org/10.1200/JCO.2004.99.058 DO - 10.1200/JCO.2004.99.058 ID - Buzdar2004 ER - TY - JOUR AU - Andre, F. AU - Neven, P. AU - Marinsek, N. AU - Zhang, J. AU - Baladi, J. F. AU - Degun, R. PY - 2014 DA - 2014// TI - Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer JO - Curr Med Res Opin. VL - 30 UR - https://doi.org/10.1185/03007995.2014.887002 DO - 10.1185/03007995.2014.887002 ID - Andre2014 ER - TY - JOUR AU - Muss, H. B. AU - Case, L. D. AU - Atkins, J. N. AU - Bearden, J. D. AU - Cooper, M. R. AU - Cruz, J. M. PY - 1994 DA - 1994// TI - Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study JO - J Clin Oncol. VL - 12 ID - Muss1994 ER - TY - JOUR AU - Ellis, M. J. AU - Gao, F. AU - Dehdashti, F. AU - Jeffe, D. B. AU - Marcom, P. K. AU - Carey, L. A. PY - 2009 DA - 2009// TI - Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study JO - JAMA. VL - 302 UR - https://doi.org/10.1001/jama.2009.1204 DO - 10.1001/jama.2009.1204 ID - Ellis2009 ER - TY - JOUR AU - Iwase, H. AU - Yamamoto, Y. AU - Yamamoto-Ibusuki, M. AU - Murakami, K. I. AU - Okumura, Y. AU - Tomita, S. PY - 2013 DA - 2013// TI - Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study JO - Br J Cancer. VL - 109 UR - https://doi.org/10.1038/bjc.2013.520 DO - 10.1038/bjc.2013.520 ID - Iwase2013 ER - TY - JOUR AU - Abraham, J. E. AU - Maranian, M. J. AU - Driver, K. E. AU - Platte, R. AU - Kalmyrzaev, B. AU - Baynes, C. PY - 2010 DA - 2010// TI - CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen JO - Breast Cancer Res. VL - 12 UR - https://doi.org/10.1186/bcr2629 DO - 10.1186/bcr2629 ID - Abraham2010 ER - TY - JOUR AU - Wang, L. AU - Ellsworth, K. A. AU - Moon, I. AU - Pelleymounter, L. L. AU - Eckloff, B. W. AU - Martin, Y. N. PY - 2010 DA - 2010// TI - Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors JO - Cancer Res. VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-3224 DO - 10.1158/0008-5472.CAN-09-3224 ID - Wang2010 ER - TY - JOUR AU - Jin, Y. AU - Desta, Z. AU - Stearns, V. AU - Ward, B. AU - Ho, H. AU - Lee, K. H. PY - 2005 DA - 2005// TI - CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment JO - J Natl Cancer Inst. VL - 97 UR - https://doi.org/10.1093/jnci/dji005 DO - 10.1093/jnci/dji005 ID - Jin2005 ER - TY - JOUR AU - Ferraldeschi, R. AU - Arnedos, M. AU - Hadfield, K. D. AU - A'Hern, R. AU - Drury, S. AU - Wardley, A. PY - 2012 DA - 2012// TI - Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients JO - Breast Cancer Res Treat. VL - 133 UR - https://doi.org/10.1007/s10549-012-2010-z DO - 10.1007/s10549-012-2010-z ID - Ferraldeschi2012 ER - TY - JOUR AU - Binkhorst, L. AU - Mathijssen, R. H. AU - Jager, A. AU - Gelder, T. PY - 2015 DA - 2015// TI - Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping JO - Canc Treat Rev. VL - 41 UR - https://doi.org/10.1016/j.ctrv.2015.01.002 DO - 10.1016/j.ctrv.2015.01.002 ID - Binkhorst2015 ER - TY - JOUR AU - Osborne, C. K. AU - Schiff, R. PY - 2011 DA - 2011// TI - Mechanisms of endocrine resistance in breast cancer JO - Annu Rev Med. VL - 62 UR - https://doi.org/10.1146/annurev-med-070909-182917 DO - 10.1146/annurev-med-070909-182917 ID - Osborne2011 ER - TY - JOUR AU - Gewinner, C. AU - Wang, Z. C. AU - Richardson, A. AU - Teruya-Feldstein, J. AU - Etemadmoghadam, D. AU - Bowtell, D. PY - 2009 DA - 2009// TI - Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling JO - Cancer Cell. VL - 16 UR - https://doi.org/10.1016/j.ccr.2009.06.006 DO - 10.1016/j.ccr.2009.06.006 ID - Gewinner2009 ER - TY - JOUR AU - Stephens, P. J. AU - Tarpey, P. S. AU - Davies, H. AU - Loo, P. AU - Greenman, C. AU - Wedge, D. C. PY - 2012 DA - 2012// TI - The landscape of cancer genes and mutational processes in breast cancer JO - Nature. VL - 486 ID - Stephens2012 ER - TY - STD TI - Hortobagyi GN, Piccart-Gebhart MJ, HS R. Correlation of molecular alterations with efficacy of everolimus in hormone receptor–-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. J Clin Oncol 31, 2013 (suppl; abstr LBA509). ID - ref17 ER - TY - JOUR AU - Andre, F. AU - Job, B. AU - Dessen, P. AU - Tordai, A. AU - Michiels, S. AU - Liedtke, C. PY - 2009 DA - 2009// TI - Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array JO - Clin Cancer Res. VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-1791 DO - 10.1158/1078-0432.CCR-08-1791 ID - Andre2009 ER - TY - JOUR AU - Curtis, C. AU - Shah, S. P. AU - Chin, S. F. AU - Turashvili, G. AU - Rueda, O. M. AU - Dunning, M. J. PY - 2012 DA - 2012// TI - The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups JO - Nature. VL - 486 ID - Curtis2012 ER - TY - JOUR AU - Musgrove, E. A. AU - Caldon, C. E. AU - Barraclough, J. AU - Stone, A. AU - Sutherland, R. L. PY - 2011 DA - 2011// TI - Cyclin D as a therapeutic target in cancer JO - Nat Rev Cancer. VL - 11 UR - https://doi.org/10.1038/nrc3090 DO - 10.1038/nrc3090 ID - Musgrove2011 ER - TY - JOUR AU - Migliaccio, I. AU - Malorni, L. AU - Hart, C. D. AU - Guarducci, C. AU - Leo, A. PY - 2015 DA - 2015// TI - Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers JO - BMC Med. VL - 13 UR - https://doi.org/10.1186/s12916-015-0280-0 DO - 10.1186/s12916-015-0280-0 ID - Migliaccio2015 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell. VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - JOUR AU - Hirsch, E. AU - Ciraolo, E. AU - Franco, I. AU - Ghigo, A. AU - Martini, M. PY - 2014 DA - 2014// TI - PI3K in cancer-stroma interactions: bad in seed and ugly in soil JO - Oncogene. VL - 33 UR - https://doi.org/10.1038/onc.2013.265 DO - 10.1038/onc.2013.265 ID - Hirsch2014 ER - TY - JOUR AU - Samuels, Y. AU - Ericson, K. PY - 2006 DA - 2006// TI - Oncogenic PI3K and its role in cancer JO - Curr Opin Oncol. VL - 18 UR - https://doi.org/10.1097/01.cco.0000198021.99347.b9 DO - 10.1097/01.cco.0000198021.99347.b9 ID - Samuels2006 ER - TY - JOUR PY - 2012 DA - 2012// TI - Comprehensive molecular portraits of human breast tumours JO - Nature VL - 490 UR - https://doi.org/10.1038/nature11412 DO - 10.1038/nature11412 ID - ref25 ER - TY - JOUR AU - Miller, T. W. AU - Hennessy, B. T. AU - Gonzalez-Angulo, A. M. AU - Fox, E. M. AU - Mills, G. B. AU - Chen, H. PY - 2010 DA - 2010// TI - Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer JO - J Clin Invest. VL - 120 UR - https://doi.org/10.1172/JCI41680 DO - 10.1172/JCI41680 ID - Miller2010 ER - TY - JOUR AU - Simoncini, T. AU - Hafezi-Moghadam, A. AU - Brazil, D. P. AU - Ley, K. AU - Chin, W. W. AU - Liao, J. K. PY - 2000 DA - 2000// TI - Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase JO - Nature. VL - 407 UR - https://doi.org/10.1038/35035131 DO - 10.1038/35035131 ID - Simoncini2000 ER - TY - JOUR AU - DeGraffenried, L. A. AU - Fulcher, L. AU - Friedrichs, W. E. AU - Grunwald, V. AU - Ray, R. B. AU - Hidalgo, M. PY - 2004 DA - 2004// TI - Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway JO - Ann Oncol. VL - 15 UR - https://doi.org/10.1093/annonc/mdh388 DO - 10.1093/annonc/mdh388 ID - DeGraffenried2004 ER - TY - JOUR AU - Tabernero, J. AU - Rojo, F. AU - Calvo, E. AU - Burris, H. AU - Judson, I. AU - Hazell, K. PY - 2008 DA - 2008// TI - Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors JO - J Clin Oncol. VL - 26 UR - https://doi.org/10.1200/JCO.2007.14.5482 DO - 10.1200/JCO.2007.14.5482 ID - Tabernero2008 ER - TY - JOUR AU - Chan, S. AU - Scheulen, M. E. AU - Johnston, S. AU - Mross, K. AU - Cardoso, F. AU - Dittrich, C. PY - 2005 DA - 2005// TI - Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer JO - J Clin Oncol. VL - 23 UR - https://doi.org/10.1200/JCO.2005.66.130 DO - 10.1200/JCO.2005.66.130 ID - Chan2005 ER - TY - JOUR AU - Boulay, A. AU - Rudloff, J. AU - Ye, J. AU - Zumstein-Mecker, S. AU - O'Reilly, T. AU - Evans, D. B. PY - 2005 DA - 2005// TI - Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer JO - Clin Cancer Res. VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-2402 DO - 10.1158/1078-0432.CCR-04-2402 ID - Boulay2005 ER - TY - JOUR AU - Baselga, J. AU - Semiglazov, V. AU - Dam, P. AU - Manikhas, A. AU - Bellet, M. AU - Mayordomo, J. PY - 2009 DA - 2009// TI - Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer JO - J Clin Oncol. VL - 27 UR - https://doi.org/10.1200/JCO.2008.18.8391 DO - 10.1200/JCO.2008.18.8391 ID - Baselga2009 ER - TY - JOUR AU - Bachelot, T. AU - Bourgier, C. AU - Cropet, C. AU - Ray-Coquard, I. AU - Ferrero, J. M. AU - Freyer, G. PY - 2012 DA - 2012// TI - Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study JO - J Clin Oncol. VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.0708 DO - 10.1200/JCO.2011.39.0708 ID - Bachelot2012 ER - TY - JOUR AU - Baselga, J. AU - Campone, M. AU - Piccart, M. AU - Burris, H. A. AU - Rugo, H. S. AU - Sahmoud, T. PY - 2012 DA - 2012// TI - Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer JO - N Engl J Med. VL - 366 UR - https://doi.org/10.1056/NEJMoa1109653 DO - 10.1056/NEJMoa1109653 ID - Baselga2012 ER - TY - JOUR AU - Wolff, A. C. AU - Lazar, A. A. AU - Bondarenko, I. AU - Garin, A. M. AU - Brincat, S. AU - Chow, L. PY - 2013 DA - 2013// TI - Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer JO - J Clin Oncol. VL - 31 UR - https://doi.org/10.1200/JCO.2011.38.3331 DO - 10.1200/JCO.2011.38.3331 ID - Wolff2013 ER - TY - JOUR AU - Yardley, D. A. AU - Noguchi, S. AU - Pritchard, K. I. AU - Burris, H. A. AU - Baselga, J. AU - Gnant, M. PY - 2013 DA - 2013// TI - Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis JO - Adv Ther. VL - 30 UR - https://doi.org/10.1007/s12325-013-0060-1 DO - 10.1007/s12325-013-0060-1 ID - Yardley2013 ER - TY - JOUR AU - Piccart, M. AU - Hortobagyi, G. N. AU - Campone, M. AU - Pritchard, K. I. AU - Lebrun, F. AU - Ito, Y. PY - 2014 DA - 2014// TI - Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: cancer: overall survival results from BOLERO-2 JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu456 DO - 10.1093/annonc/mdu456 ID - Piccart2014 ER - TY - JOUR AU - Treilleux, I. A. M. AU - Cropet, C. AU - Ferrero, J. AU - Lacourtoisie, S. AU - Spaeth, D. PY - 2013 DA - 2013// TI - Predictive markers of everolimus efficacy in hormone receptor positive (HR+) metastatic breast cancer (MBC): final results of the TAMRAD Trial Translational Study JO - J Clin Oncol. VL - 31 UR - https://doi.org/10.1200/JCO.2012.46.0980 DO - 10.1200/JCO.2012.46.0980 ID - Treilleux2013 ER - TY - JOUR AU - Stemke-Hale, K. AU - Gonzalez-Angulo, A. M. AU - Lluch, A. AU - Neve, R. M. AU - Kuo, W. L. AU - Davies, M. PY - 2008 DA - 2008// TI - An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer JO - Cancer Res. VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-07-6854 DO - 10.1158/0008-5472.CAN-07-6854 ID - Stemke-Hale2008 ER - TY - JOUR AU - Ellis, M. J. AU - Lin, L. AU - Crowder, R. AU - Tao, Y. AU - Hoog, J. AU - Snider, J. PY - 2010 DA - 2010// TI - Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer JO - Breast Cancer Res Treat. VL - 119 UR - https://doi.org/10.1007/s10549-009-0575-y DO - 10.1007/s10549-009-0575-y ID - Ellis2010 ER - TY - JOUR AU - Campbell, I. G. AU - Russell, S. E. AU - Choong, D. Y. AU - Montgomery, K. G. AU - Ciavarella, M. L. AU - Hooi, C. S. PY - 2004 DA - 2004// TI - Mutation of the PIK3CA gene in ovarian and breast cancer JO - Cancer Res. VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-04-2933 DO - 10.1158/0008-5472.CAN-04-2933 ID - Campbell2004 ER - TY - JOUR AU - Perez-Tenorio, G. AU - Alkhori, L. AU - Olsson, B. AU - Waltersson, M. A. AU - Nordenskjold, B. AU - Rutqvist, L. E. PY - 2007 DA - 2007// TI - PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer JO - Clin Cancer Res. VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-1609 DO - 10.1158/1078-0432.CCR-06-1609 ID - Perez-Tenorio2007 ER - TY - JOUR AU - Fu, X. AU - Osborne, C. K. AU - Schiff, R. PY - 2013 DA - 2013// TI - Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer JO - Breast. VL - 22 UR - https://doi.org/10.1016/j.breast.2013.08.001 DO - 10.1016/j.breast.2013.08.001 ID - Fu2013 ER - TY - JOUR AU - Shapiro, G. I. AU - Rodon, J. AU - Bedell, C. AU - Kwak, E. L. AU - Baselga, J. AU - Brana, I. PY - 2014 DA - 2014// TI - Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors JO - Clin Cancer Res. VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-1777 DO - 10.1158/1078-0432.CCR-13-1777 ID - Shapiro2014 ER - TY - JOUR AU - Sarker, D. AU - Ang, J. E. AU - Baird, R. AU - Kristeleit, R. AU - Shah, K. AU - Moreno, V. PY - 2015 DA - 2015// TI - First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors JO - Clin Cancer Res. VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-0947 DO - 10.1158/1078-0432.CCR-14-0947 ID - Sarker2015 ER - TY - JOUR AU - Maira, S. M. AU - Pecchi, S. AU - Huang, A. AU - Burger, M. AU - Knapp, M. AU - Sterker, D. PY - 2012 DA - 2012// TI - Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor JO - Mol Canc Therapeut. VL - 11 UR - https://doi.org/10.1158/1535-7163.MCT-11-0474 DO - 10.1158/1535-7163.MCT-11-0474 ID - Maira2012 ER - TY - JOUR AU - Rodon, J. AU - Brana, I. AU - Siu, L. L. AU - Jonge, M. J. AU - Homji, N. AU - Mills, D. PY - 2014 DA - 2014// TI - Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors JO - Investig New Drugs. VL - 32 UR - https://doi.org/10.1007/s10637-014-0082-9 DO - 10.1007/s10637-014-0082-9 ID - Rodon2014 ER - TY - JOUR AU - Mayer, I. A. AU - Abramson, V. G. AU - Isakoff, S. J. AU - Forero, A. AU - Balko, J. M. AU - Kuba, M. G. PY - 2014 DA - 2014// TI - Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer JO - J Clin Oncol. VL - 32 UR - https://doi.org/10.1200/JCO.2013.54.0518 DO - 10.1200/JCO.2013.54.0518 ID - Mayer2014 ER - TY - JOUR AU - Juric, D. AU - Rodon, J. AU - Gonzalez-Angulo, A. AU - Burris, H. A. AU - Bendel, J. AU - Berlin, J. PY - 2012 DA - 2012// TI - BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study JO - Cancer Res. VL - 72 UR - https://doi.org/10.1158/1538-7445.AM2012-1 DO - 10.1158/1538-7445.AM2012-1 ID - Juric2012 ER - TY - JOUR AU - Shah, O. J. AU - Wang, Z. AU - Hunter, T. PY - 2004 DA - 2004// TI - Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies JO - Curr Biol. VL - 14 UR - https://doi.org/10.1016/j.cub.2004.08.026 DO - 10.1016/j.cub.2004.08.026 ID - Shah2004 ER - TY - JOUR AU - Gupta, S. AU - Ramjaun, A. R. AU - Haiko, P. AU - Wang, Y. AU - Warne, P. H. AU - Nicke, B. PY - 2007 DA - 2007// TI - Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice JO - Cell. VL - 129 UR - https://doi.org/10.1016/j.cell.2007.03.051 DO - 10.1016/j.cell.2007.03.051 ID - Gupta2007 ER - TY - JOUR AU - Zhang, H. AU - Bajraszewski, N. AU - Wu, E. AU - Wang, H. AU - Moseman, A. P. AU - Dabora, S. L. PY - 2007 DA - 2007// TI - PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR JO - J Clin Invest. VL - 117 UR - https://doi.org/10.1172/JCI28984 DO - 10.1172/JCI28984 ID - Zhang2007 ER - TY - STD TI - Edelman G, Bedell C, Shapiro G, Pandya SS, Kwak EL, Scheffold C, et al. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol. 28:15s, 2010 (suppl; abstr 3004). ID - ref53 ER - TY - STD TI - Krop I, Johnston S, Mayer A, Dickler M, Ganju V, Forero-Torres A. FERGI phase II study of PI3K inhibitor Pictilisibpictilisib (GDC-0941) plus fulvestrant vs Fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer - Part I results. Cancer Research. 05/2015; 75(9 Supplement). ID - ref54 ER - TY - JOUR AU - Roberts, P. J. AU - Bisi, J. E. AU - Strum, J. C. AU - Combest, A. J. AU - Darr, D. B. AU - Usary, J. E. PY - 2012 DA - 2012// TI - Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy JO - J Natl Cancer Inst. VL - 104 UR - https://doi.org/10.1093/jnci/djs002 DO - 10.1093/jnci/djs002 ID - Roberts2012 ER - TY - JOUR AU - Lange, C. A. AU - Yee, D. PY - 2011 DA - 2011// TI - Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. (Endocr Relat JO - Cancer. VL - 18 ID - Lange2011 ER - TY - JOUR AU - Finn, R. S. AU - Dering, J. AU - Conklin, D. AU - Kalous, O. AU - Cohen, D. J. AU - Desai, A. J. PY - 2009 DA - 2009// TI - PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro JO - Breast Cancer Res. VL - 11 UR - https://doi.org/10.1186/bcr2419 DO - 10.1186/bcr2419 ID - Finn2009 ER - TY - JOUR AU - Finn, R. S. AU - Crown, J. P. AU - Lang, I. AU - Boer, K. AU - Bondarenko, I. M. AU - Kulyk, S. O. PY - 2015 DA - 2015// TI - The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study JO - Lancet Oncol. VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71159-3 DO - 10.1016/S1470-2045(14)71159-3 ID - Finn2015 ER - TY - STD TI - Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Leena Gandhi L, et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer. Cancer Res 2014;74:Abstract nr CT232. ID - ref59 ER - TY - JOUR AU - Vora, S. R. AU - Juric, D. AU - Kim, N. AU - Mino-Kenudson, M. AU - Huynh, T. AU - Costa, C. PY - 2014 DA - 2014// TI - CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors JO - Cancer Cell. VL - 26 UR - https://doi.org/10.1016/j.ccr.2014.05.020 DO - 10.1016/j.ccr.2014.05.020 ID - Vora2014 ER - TY - JOUR AU - Turner, N. AU - Pearson, A. AU - Sharpe, R. AU - Lambros, M. AU - Geyer, F. AU - Lopez-Garcia, M. A. PY - 2010 DA - 2010// TI - FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer JO - Cancer Res. VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-3746 DO - 10.1158/0008-5472.CAN-09-3746 ID - Turner2010 ER - TY - JOUR AU - Andre, F. AU - Bachelot, T. AU - Commo, F. AU - Campone, M. AU - Arnedos, M. AU - Dieras, V. PY - 2014 DA - 2014// TI - Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER) JO - Lancet Oncol. VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70611-9 DO - 10.1016/S1470-2045(13)70611-9 ID - Andre2014 ER - TY - JOUR AU - Andre, F. AU - Bachelot, T. AU - Campone, M. AU - Dalenc, F. AU - Perez-Garcia, J. M. AU - Hurvitz, S. A. PY - 2013 DA - 2013// TI - Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer JO - Clin Cancer Res. VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0190 DO - 10.1158/1078-0432.CCR-13-0190 ID - Andre2013 ER - TY - JOUR AU - Sengupta, N. AU - Seto, E. PY - 2004 DA - 2004// TI - Regulation of histone deacetylase activities JO - J Cell Biochem. VL - 93 UR - https://doi.org/10.1002/jcb.20179 DO - 10.1002/jcb.20179 ID - Sengupta2004 ER - TY - JOUR AU - Fischle, W. AU - Wang, Y. AU - Allis, C. D. PY - 2003 DA - 2003// TI - Binary switches and modification cassettes in histone biology and beyond JO - Nature. VL - 425 UR - https://doi.org/10.1038/nature02017 DO - 10.1038/nature02017 ID - Fischle2003 ER - TY - JOUR AU - Bolden, J. E. AU - Peart, M. J. AU - Johnstone, R. W. PY - 2006 DA - 2006// TI - Anticancer activities of histone deacetylase inhibitors JO - Nat Rev Drug Discov. VL - 5 UR - https://doi.org/10.1038/nrd2133 DO - 10.1038/nrd2133 ID - Bolden2006 ER - TY - JOUR AU - Marks, P. AU - Rifkind, R. A. AU - Richon, V. M. AU - Breslow, R. AU - Miller, T. AU - Kelly, W. K. PY - 2001 DA - 2001// TI - Histone deacetylases and cancer: causes and therapies JO - Nat Rev Cancer. VL - 1 UR - https://doi.org/10.1038/35106079 DO - 10.1038/35106079 ID - Marks2001 ER - TY - JOUR AU - Dokmanovic, M. AU - Marks, P. A. PY - 2005 DA - 2005// TI - Prospects: histone deacetylase inhibitors JO - J Cell Biochem. VL - 96 UR - https://doi.org/10.1002/jcb.20532 DO - 10.1002/jcb.20532 ID - Dokmanovic2005 ER - TY - JOUR AU - Piekarz, R. L. AU - Sackett, D. L. AU - Bates, S. E. PY - 2007 DA - 2007// TI - Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy JO - Cancer J (Sudbury, Mass) VL - 13 UR - https://doi.org/10.1097/PPO.0b013e31803c73cc DO - 10.1097/PPO.0b013e31803c73cc ID - Piekarz2007 ER - TY - JOUR AU - Yu, C. AU - Rahmani, M. AU - Conrad, D. AU - Subler, M. AU - Dent, P. AU - Grant, S. PY - 2003 DA - 2003// TI - The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571 JO - Blood. VL - 102 UR - https://doi.org/10.1182/blood-2003-03-0737 DO - 10.1182/blood-2003-03-0737 ID - Yu2003 ER - TY - JOUR AU - Margueron, R. AU - Duong, V. AU - Castet, A. AU - Cavailles, V. PY - 2004 DA - 2004// TI - Histone deacetylase inhibition and estrogen signalling in human breast cancer cells JO - Biochem Pharmacol. VL - 68 UR - https://doi.org/10.1016/j.bcp.2004.04.031 DO - 10.1016/j.bcp.2004.04.031 ID - Margueron2004 ER - TY - JOUR AU - Munster, P. N. AU - Thurn, K. T. AU - Thomas, S. AU - Raha, P. AU - Lacevic, M. AU - Miller, A. PY - 2011 DA - 2011// TI - A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer JO - Br J Cancer. VL - 104 UR - https://doi.org/10.1038/bjc.2011.156 DO - 10.1038/bjc.2011.156 ID - Munster2011 ER - TY - JOUR AU - Yardley, D. A. AU - Ismail-Khan, R. R. AU - Melichar, B. AU - Lichinitser, M. AU - Munster, P. N. AU - Klein, P. M. PY - 2013 DA - 2013// TI - Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor JO - J Clin Oncol. VL - 31 UR - https://doi.org/10.1200/JCO.2012.43.7251 DO - 10.1200/JCO.2012.43.7251 ID - Yardley2013 ER - TY - JOUR AU - Ali, A. AU - Bluteau, O. AU - Messaoudi, K. AU - Palazzo, A. AU - Boukour, S. AU - Lordier, L. PY - 2013 DA - 2013// TI - Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms JO - Cell Death Dis. VL - 4 UR - https://doi.org/10.1038/cddis.2013.260 DO - 10.1038/cddis.2013.260 ID - Ali2013 ER - TY - JOUR AU - Robinson, D. R. AU - Wu, Y. M. AU - Vats, P. AU - Su, F. AU - Lonigro, R. J. AU - Cao, X. PY - 2013 DA - 2013// TI - Activating ESR1 mutations in hormone-resistant metastatic breast cancer JO - Nat Genet. VL - 45 UR - https://doi.org/10.1038/ng.2823 DO - 10.1038/ng.2823 ID - Robinson2013 ER - TY - JOUR AU - Toy, W. AU - Shen, Y. AU - Won, H. AU - Green, B. AU - Sakr, R. A. AU - Will, M. PY - 2013 DA - 2013// TI - ESR1 ligand-binding domain mutations in hormone-resistant breast cancer JO - Nat Genet. VL - 45 UR - https://doi.org/10.1038/ng.2822 DO - 10.1038/ng.2822 ID - Toy2013 ER - TY - JOUR AU - Jeselsohn, R. AU - Yelensky, R. AU - Buchwalter, G. AU - Frampton, G. AU - Meric-Bernstam, F. AU - Gonzalez-Angulo, A. M. PY - 2014 DA - 2014// TI - Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer JO - Clin Cancer Res. VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2332 DO - 10.1158/1078-0432.CCR-13-2332 ID - Jeselsohn2014 ER - TY - JOUR AU - Yu, M. AU - Bardia, A. AU - Aceto, N. AU - Bersani, F. AU - Madden, M. W. AU - Donaldson, M. C. PY - 2014 DA - 2014// TI - Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility JO - Science. VL - 345 UR - https://doi.org/10.1126/science.1253533 DO - 10.1126/science.1253533 ID - Yu2014 ER -